Tricuspid atresia primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 7: | Line 7: | ||
==Overview== | ==Overview== | ||
== | ==Primary prevention == | ||
* Effective measures for the [[primary prevention ]] of [[tricuspid atresia]] as [[prenatal screening]] include:<ref name="GalindoComas2009">{{cite journal|last1=Galindo|first1=A.|last2=Comas|first2=C.|last3=Martínez|first3=J. M.|last4=Gutiérrez-Larraya|first4=F.|last5=Carrera|first5=J. M.|last6=Puerto|first6=B.|last7=Borrell|first7=A.|last8=Mortera|first8=C.|last9=de la Fuente|first9=P.|title=Cardiac defects in chromosomally normal fetuses with increased nuchal translucency at 10–14 weeks of gestation|journal=The Journal of Maternal-Fetal & Neonatal Medicine|volume=13|issue=3|year=2009|pages=163–170|issn=1476-7058|doi=10.1080/jmf.13.3.163.170}}</ref> | * Effective measures for the [[primary prevention ]] of [[tricuspid atresia]] as [[prenatal screening]] include:<ref name="GalindoComas2009">{{cite journal|last1=Galindo|first1=A.|last2=Comas|first2=C.|last3=Martínez|first3=J. M.|last4=Gutiérrez-Larraya|first4=F.|last5=Carrera|first5=J. M.|last6=Puerto|first6=B.|last7=Borrell|first7=A.|last8=Mortera|first8=C.|last9=de la Fuente|first9=P.|title=Cardiac defects in chromosomally normal fetuses with increased nuchal translucency at 10–14 weeks of gestation|journal=The Journal of Maternal-Fetal & Neonatal Medicine|volume=13|issue=3|year=2009|pages=163–170|issn=1476-7058|doi=10.1080/jmf.13.3.163.170}}</ref> | ||
Revision as of 06:12, 28 August 2020
|
Tricuspid atresia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenarios |
|
Case Studies |
|
Tricuspid atresia primary prevention On the Web |
|
American Roentgen Ray Society Images of Tricuspid atresia primary prevention |
|
Risk calculators and risk factors for Tricuspid atresia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor-In-Chief:; Sara Zand, M.D.[2] Keri Shafer, M.D. [3] Priyamvada Singh, MBBS [4]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [5]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Primary prevention
- Effective measures for the primary prevention of tricuspid atresia as prenatal screening include:[1]
- Fetal sonography between 10-14 weeks of pregnancy for measurement of nuchal translucency thickness.
- Fetal echocardiography between 18-22 weeks of pregnancy
References
- ↑ Galindo, A.; Comas, C.; Martínez, J. M.; Gutiérrez-Larraya, F.; Carrera, J. M.; Puerto, B.; Borrell, A.; Mortera, C.; de la Fuente, P. (2009). "Cardiac defects in chromosomally normal fetuses with increased nuchal translucency at 10–14 weeks of gestation". The Journal of Maternal-Fetal & Neonatal Medicine. 13 (3): 163–170. doi:10.1080/jmf.13.3.163.170. ISSN 1476-7058.